POLR3B-associated leukodystrophy: clinical, neuroimaging and molecular-genetic analyses in four patients: clinical heterogeneity and novel mutations in POLR3B gene by Kulhánek, Jan et al.
369www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Neurologia i Neurochirurgia Polska
Polish Journal of Neurology and Neurosurgery
2019, Volume 53, no. 5, pages: 369–376
DOI: 10.5603/PJNNS.a2019.0042
Copyright © 2019 Polish Neurological Society 
ISSN 0028–3843
RESEARCH PAPER
Address for correspondence: Markéta Tesařová, Department of Paediatric and Adolescent Medicine, 1st Faculty of Medicine, Charles University and Gene-
ral University Hospital in Prague, KeKarlovu 2, 12109 Prague, Czech Republic, e-mail: marketa.tesarova@vfn.cz
POLR3B-associated leukodystrophy: clinical, neuroimaging 
and molecular-genetic analyses in four patients: clinical  
heterogeneity and novel mutations in POLR3B gene
Jan Kulhánek1, Klára Brožová2, Hana Hansíková1, Alžběta Vondráčková1, Viktor Stránecký1,  
Jan Šenkyřík3, Stanislav Kmoch1, Jiří Zeman1, Tomáš Honzík1, Markéta Tesařová1
1Department of Paediatric and Adolescent Medicine, 1st Faculty of Medicine, Charles University and General University Hospital,  
Prague, Czech Republic 
2Department of Paediatric Neurology, Thomayer Hospital, Prague, Czech Republic 
3Department of Paediatric Radiology, University Hospital Brno, Czech Republic
ABSTRACT 
Introduction and aim of the study. White matter disorders represent a spectrum of neurological diseases frequently associated 
with an unfavourable prognosis and a delay in diagnostics. We report the broad phenotypic spectrum of a rare hypomyelina-
ting leukodystrophy and three novel mutations. Further, we aim to explore the role of the combined clinical and neuroimaging 
diagnostic approach in the era of whole exome sequencing. 
Materials and methods. We present a clinical, neuroimaging and molecular-genetic characterisation of four patients from 
three families suffering from a rare genetic leukoencephalopathy. Two severely affected siblings (P1, P2) manifested a profound 
developmental delay, cerebellar symptomatology, microcephaly, failure to thrive, short stature and delayed teeth eruption with 
oligodontia. The other two patients (P3, P4), on the contrary, suffer from substantially less serious impairment with mild to mo-
derate developmental delay and cerebellar symptomatology, delayed teeth eruption, or well-manageable epilepsy. In all four 
patients, magnetic resonance revealed cerebellar atrophy and supratentorial hypomyelination with T2-weight hypointensities 
in the areas of the ventrolateral thalamic nuclei, corticospinal tract and the dentate nuclei. 
Results. Using whole-exome sequencing in P1, P2 and P3, and targeted sequencing in P4, pathogenic variants were disclosed 
in POLR3B, a gene encoding one of 17 subunits of DNA-dependent RNA polymerase III — all patients were compound heterozy-
gotes for point mutations. Three novel mutations c.727A>G (p.Met243Val) and c.2669G>A (p.Arg890His) (P1, P2), and c.1495G>A 
(p.Met499Val) (P3) were found. Magnetic resonance revealed the characteristic radiological pattern of POLR3-leukodystrophies in 
our patients. 
Conclusion and clinical implications. The diagnosis of POLR3-associated leukodystrophies can be significantly accelerated 
using the combined clinical and neuroradiological recognition pattern. Therefore, it is of crucial importance to raise the aware-
ness of this rare disorder among clinicians. Molecular-genetic analyses are indispensable for a swift diagnosis confirmation in 
cases of clear clinical suspicion, and for diagnostic search in patients with less pronounced symptomatology. They represent an 
invaluable tool for unravelling the complex genetic background of heritable white matter disorders. 
Key words: POLR3B, DNA-dependent RNA polymerase III, leukodystrophy, hypomyelination, hypodontia
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Introduction 
Leukodystrophies represent a heterogenous group of 
heritable neurological disorders affecting the white matter of 
the central nervous system (CNS) with or without peripheral 
nervous system involvement [1]. They can be differentiated 
into hypomyelinating and demyelinating leukodystrophies 
using CNS magnetic resonance imaging (MRI) recognition 
patterns. CNS MRI in demyelinating leukodystrophies shows 
prominent hyperintensity of the white matter in the T2-weig-
hted (T2-W) sequence and hypointensity in the T1-weighted 
(T1-W) sequence, as opposed to hypomyelinating leukodys-
trophies in which mild white matter hyperintensity on T2-W 
sequence and mild hypo-, iso- or hyperintensity on T1-W 
sequence can be observed [1, 2, 3]. The radiological criteria 
for hypomyelination further require an unchanged pattern of 
deficient myelination on two successive MRI scans at least six 
months apart, and at least one of them performed after the age 
of one year, separating thus delayed myelination and hypomy-
elination [2]. At least 91 heritable disorders affecting the white 
matter are known, 30 of which are the classic leukodystrop-
hies with primary myelin infliction, the rest being formed by 
genetic leukoencephalopathies in which myelin homeostasis 
disruption is part of a systemic metabolic disorder [1].
The DNA-dependent RNA polymerase III-associated 
(POLR3-associated) leukodystrophies comprise a set of clini-
cally, radiologically and genetically defined, yet heterogeneous, 
hypomyelinating leukodystrophies, for which a common 
aetiopathogenesis has been disclosed recently – mutations in 
the POLR3A, POLR3B, and POLR1C genes encoding subunits 
of the DNA-dependent RNA polymerase III. The prominent 
clinical symptoms of POLR3-associated leukodystrophies 
include progressive motor dysfunction or regression with 
hypotonia and marked cerebellar and pyramidal or extrapyra-
midal signs with a variable degree of intellectual impairment. 
Dental abnormalities constitute a distinct clinical sign. The 
severity of impairment may vary greatly among individual 
patients, and the disease may present in several distinct phe-
notypic forms. A specific radiological pattern exists offering 
a highly sensitive and specific diagnostic tool. Currently, only 
supportive symptomatic treatment exists [4–9].
Here, we present a thorough clinical, neuroimaging and 
molecular-genetic characterisation of four patients from three 
unrelated families. The sibling patients (P1, P2) presented 
severe both neurological and non-neurological phenotypes 
with early onset and rapid disease progression with profound 
developmental delay, various intriguing clinical features, and 
hypomyelination on CNS MRI. The other two patients (P3, 
P4) developed similar MRI findings, although they were much 
less dramatically affected with mild to moderate intellectual 
disability and other somatic symptoms that were fewer and 
less distinctly pronounced. Compound heterozygosity for 
mutations in POLR3B gene was found in all the patients, and 
three previously unreported mutations were revealed. 
Case reports 
Two affected siblings (P1, P2) and two other unrelated 
patients (P3, P4) born to healthy non-consanguineous parents 
are presented (Tab. 1). 
P1, P2: The older sister (P1) was born prematurely in the 
34th week of gestation with adequate birth weight of 2,300 g 
and length of 44 cm. The imminent postnatal adaptation was 
uneventful with an Apgar score of 9-10-10. Due to an early 
postnatal infection, the girl had had to be temporarily treated 
with antibiotics since her second day of life; however, reco-
very occurred within days, and discharge from hospital in 
a good clinical condition followed. Psychomotor milestones 
achievement was satisfactory until the age of six months, 
when a developmental deceleration and arrest were observed. 
Subsequently, the girl’s clinical state started to deteriorate mar-
kedly. During regular clinical evaluations, she began to present 
with profound psychomotor retardation, central hypotonic 
syndrome, and a progressive cerebellar symptomatology. The 
prominent evolving features were dysmetria, dyskinetic cho-
reatic movements, lower extremities spasticity, failure to thrive 
(17 kg, < 1st percentile at 10 years), short stature (114 cm, < 1st 
percentile at 10 years), microcephaly (45 cm, < 1st percentile 
at 10 years), convergent strabismus, central nystagmus, optic 
nerve atrophy, hypertelorism, inverted mammils and oligo-
dontia with atypical teeth shape, and delayed eruption of both 
deciduous and permanent teeth (Fig. 1). Her clinical state is 
now still slowly progressive, predominantly concerning the 
cerebellar symptomatology. At the age of 11, she is neither able 
to sit nor to walk, and her cognitive development corresponds 
to the 3rd trimenone. 
The second sister (P2) was born at term with a birth weight 
of 3,220 g and birth length of 49 cm. The clinical course and 
disease progression were very similar to her sister. At the age 
of seven months, developmental slowdown and practical arrest 
occurred. Progressively, substantial psychomotor retardation, 
hypotonic syndrome and cerebellar symptomatology evolved, 
with tremor, acral dyskinesias, failure to thrive (12.5 kg, < 1st 
percentile at six years), short stature (100 cm, < 1st percentile 
at 5.5 years), microcephaly (45 cm, < 1st percentile at six years), 
craniofacial dysmorphia (hypertelorism, enlarged auricles, 
mild macroglossia), strabismus, hypermetropia, inverted 
mammils and abnormal dental findings with oligodontia and 
delayed deciduous and permanent teeth eruption (Fig. 1). At 
the age of seven years, showing mild intrafamilial difference, 
she is able to sit unassisted and recently began to stand up and 
walk around the furniture, milestones her older sister never 
achieved . Her cognitive development is approximately at the 
level of eight months. Similarly to her sister, the cerebellar 
symptomatology is currently slowly progressive.
In both sisters, biochemical work-up did not reveal any ab-
normalities. Genetic analyses including micro-array hybridisa-
tion assays (aCGH) and targeted gene (MECP2, SMN1) analyses 
were negative. Thorough metabolic evaluation was also normal.
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Figure 1. Oligodontia of P2 at the age of 6 years due to delayed 
eruption of both the deciduous and permanent teeth with atypical-
ly shaped teeth and enamel hypoplasia 
Table 1. Clinical symptoms in two severely (P1, P2) and two moderately (P3, P4) impaired patients with three novel variants in POLR3B gene and their com-
parison to literature 
Clinical feature Patient 1 Patient 2 Patient 3 Patient 4 Wolf et al., 2014 
n = 103
Age of onset 6 months 7 months 3 years 2 years < 10 years (90%)
Age at referral 10 years 6 years n.d.
Developmental delay + + + + most patients
Hypotonia + + - + n.d.
Ataxia + + + + almost all patients
Tremor - + - + many patients
Dyskinesias - + + + a few patients
Acral spasticity + - + + +
Epilepsy - - + -  19%
Dental abnormalities + + - + 87%
Delayed dentition + + - +  71%
Hypo- /oligodontia + + - + 72%
Abnormal teeth shape + + - + +
Microcephaly + + - - n.d.
Short stature + + - n.d.  51 %
Failure to thrive + + - - n.d.
Facial dysmorphy + + - - n.d.
Inverted mammils + + - - n.d.
Strabismus + + - - n.d.
Nystagmus + + - - most patients
Optic atrophy + - + - +
Myopia - - + + 87%
Hypermetropia - + - - n.d.
n.d. — not determined
P3: The perinatal data of the currently 28 year-old male 
P3 document delayed imminent postnatal adaptation necessi-
tating resuscitation. Nevertheless, further development was 
unremarkable and appropriate until three years of age when 
slow retardation of psychomotor milestones achievement 
started to become apparent. Subsequently, apart from in the 
long term almost stationary mild psychomotor delay, clumsi-
ness and behavioural problems began to develop. The clinical 
state then remained for a long time without any substantial 
progress. The patient attended a regular elementary school 
initially. Later on, however, he had to be assigned to a special 
educational programme. At the age of 11 years, the first epi-
leptic seizure of a generalised tonic-clonic nature appeared. 
Antiepileptic therapy was initiated with a satisfactory effect, 
and epilepsy has since then been well-managed. In subsequent 
years, however, the patient’s communication skills deteriora-
ted mildly, and mood oscillations were noted. Furthermore, 
cerebellar and extrapyramidal symptomatology developed 
during the second decade of life and started to dominate the 
clinical picture, including ataxia, dyskinetic movements of 
the extremities and the neck, and hyperreflexia with hyp-/
paresthesias of the lower limbs. Also, the patient’s behavioural 
disorder then progressed with sexually inappropriate behavio-
ur being noted. Psychological examination objectified a be-
low average performance in the majority of the areas tested. 
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Marked myopia required ophthalmological correction. Due 
to the development of gynaecomastia, the patient underwent 
a thorough endocrinological examination, which yielded no 
abnormal findings. Neither dental abnormalities, nor growth 
impairment, failure to thrive, nor any other conspicuous 
symptoms were observed. 
For the time being, the patient’s clinical state seems to 
remain stationary, except for mild worsening of his cognitive 
functions. 
Complex biochemical and metabolic workup were incon-
clusive, as were genetic analyses including the common mic-
rodeletion syndromes and X-linked mental retardations panel. 
P4: Patient 4 is a 19 year-old woman born without any 
perinatal burden and with physiological birth anthropometric 
data. The early developmental milestones achievement rema-
ined within broader limits until two years of age, when mild 
psychomotor impairment started to become apparent. Teeth 
eruption was already delayed at that time. Simultaneously, 
growth velocity slowdown occurred and insufficient growth 
hormone production was confirmed. Substitution treatment 
was therefore initialised, with a satisfactory response. At aro-
und three years of age, apart from the developmental delay, 
intentional tremor with clumsiness and ataxia with frequent 
falls came to the forefront of the phenotypic picture and set 
off a broad diagnostic process. The patient’s clinical condition 
subsequently slowly progressed, dominantly in the cerebellar 
component; choreiform dyskinesias and hyperreflexia together 
with pyramidal signs were noted further on. The absence 
of any signs of puberty initiation provoked endocrinology 
examinations disclosing borderline levels of both central and 
peripheral sex-hormones. Thus, hormonal substitution therapy 
was commenced. However, psychiatric problems including 
depression, food refusal and pseudohallucinations occurred 
thereafter. These  were judged however to be a possible adverse 
consequence of the hormonal therapy. Another CNS MR at 
16 years of age revealed mild progression of the cerebellar 
atrophy; yet the neurological findings of the cerebellar symp-
tomatology seem to be long-term stationary. In summary, the 
current clinical state of P4 is non-progressive and dominated 
by mild intellectual disability, cerebellar symptomatology, op-
tic atrophy and markedly disrupted dental eruption resulting 
in oligodontia with abnormally shaped teeth. 
As with the other patients, biochemical and metabolic 
examinations remained unremarkable. Genetic testing, aiming 
at e.g. various spinocerebellar ataxias, yielded no results.
Material and methods
Exome sequencing of the trio (proband(s) and unaffec-
ted parents; P1, P2, P3) was performed using an Illumina 
HiSeq 2000 system (Illumina, USA) and SeqCap EZ Exome 
Enrichment kit v3.0 (Roche NimbleGen, USA) [10]. Sanger se-
quencing of all exons and exon–intron boundaries of POLR3B 
gene (NG_031837.1, NM_018082.5) was used in P4. POLR3B 
mutations identified by exome sequencing were confirmed by 
Sanger sequencing in probands and their parents. 
Ethics 
This study was approved by the ethics committee of the 
General University Hospital in Prague and was conducted in 
agreement with institutional guidelines. Written informed 
consent was obtained from parents for genetic analysis.
Results and Discussion
Mutations affecting POLR3 subunits, in particular the two 
largest subunits POLR3A (DNA-dependent RNA-polymerase 
III, subunit A) and POLR3B (DNA-dependent RNA-polymera-
se III, subunit B), are causative of a continuous spectrum of al-
lelic and clinically, radiologically and genetically defined group 
of hypomyelinating leukodystrophic disorders categorised as 
POLR3-associated leukodystrophies. This group includes five 
disorders initially described as individual entities: Hypomy-
elination with Oligodontia (HO), Tremor-Ataxia with Central 
Hypomyelination (TACH), Hypomyelination with Cerebellar 
Atrophy and Hypoplasia of the Corpus Callosum (HCAHCC), 
Ataxia, Delayed Dentition and Hypomyelination (ADDH) 
and Hypomyelination, Hypodontia, Hypogonadotropic Hy-
pogonadism (4H). With the expansion of molecular genetic 
testing, these disorders have been revealed to have a similar 
genetic basis: mutations in genes encoding for POLR3 subu-
nits. Therefore, rather than separate diseases, they represent 
a broad phenotypic spectrum with distinct phenotypes of the 
so-called POLR3-associated leukodystrophies [11, 12, 13]. 
They represent an extremely rare disorder with single case 
reports reported worldwide. However, as there is no database 
gathering these patients, neither the precise number of patients 
suffering from POLR3-associated leukodystrophies nor other 
epidemiological data are currently available. No more than 
a few hundred patients have been reported in the literature, 
the largest cohort amounting to 105 patients [11]. Genetic 
testing in our patient cohort revealed that all patients were 
compound heterozygotes for point mutations in POLR3B gene, 
a gene encoding one of the 17 subunits of the DNA-dependent 
RNA polymerase III. 
In P1 and P2, with the severe phenotype, two novel 
heterozygous mutations — maternally inherited c.727A>G 
(p.Met243Val) and paternally inherited c.2669G>A 
(p.Arg890His) — were found. Using exome sequencing, P3 was 
found to bear a novel variant c.1495G>A (p.Met499Val) inheri-
ted from his mother and a previously characterised pathogenic 
variant c.2084-6A>G leading to a frameshift and a premature 
stop codon (p.Gly695Valfs*5) [5]. The novel variants change 
evolutionally conserved amino acids. The impact of these three 
missense mutations on POLR3B was assessed with Mutation-
Taster [14], PolyPhen2 [15] and SIFT [16] programmes and 
mutations were predicted to be pathogenic. Sequence analysis 
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Table 2. MRI findings in two severely (P1, P2) and two moderately (P3, P4) impaired patients with three novel variants in POLR3B gene
MRI feature Patient 1 Patient 2 Patient 3 Patient 4
Age at MRI examination (years) 10 5 15 16
Diffuse supratentorial hypomyelination + + + +
T2-weight hypointensities
 ventrolateral thalamus + + + +
 globus pallidus - - + +
 corticospinal tracts (internal capsule) + + + +
 nucleus dentatus + + + +
 optic radiation - - - -
Cerebellar atrophy + + + +
Cortical dysplasia + + - -
Arachnoideal cysts - + - -
of the POLR3B in P4 revealed compound heterozygosity for 
two reported mutations, a frameshift variant c.2570+1G>A 
leading to a premature truncated protein (p.Gly818fs), and 
a common missense mutation c.1568T>A (p.Val523Glu) found 
in patients from a European background, homozygosity of 
which causes a milder phenotype. Apart from this exception, 
patients with compound heterozygous mutations show no 
difference in disease progression from those bearing homo-
zygous mutations [17]. 
POLR3 is one of the three DNA-dependent RNA poly-
merases found in eukaryotic cell nuclei, each of them being 
responsible for the transcription of a specific set of ge-
nes [5, 18]. POLR3 transcribes a number of various non-
-coding RNAs involved in essential cellular processes such 
as translation, RNA processing or transcription regulation 
[19]. POLR3 is composed of 17 subunits, the two largest 
of which, POLR3A and POLR3B, form the catalytic centre 
of the enzyme and are responsible for the vast majority of 
POLR3-associated leukodystrophies [11, 18]. A mutation in 
POLR1C – a POLR1 (DNA-dependent RNA polymerase I) 
and POLR3 shared subunit previously associated with the 
autosomal recessive Treacher Collins syndrome, has recently 
been proved to also be causative of a minority of cases of 
POLR3-associated leukodystrophies [20].
The pathophysiological pathway underlying POLR3-leu-
kodystrophies remains elusive. However, it is presumed that 
either defective POLR3 assembly, stability or nuclear import 
or decreased enzymatic activity could affect the levels of va-
rious RNAs, which in turn are indispensable for embryonic 
CNS myelin formation and subsequent myelin homeostasis 
[5]. POLR3 function is cell-type and cell-cycle dependent. 
With certain transcripts being brain-specific, this might be 
the mechanism partially explanatory of the profound CNS 
impairment and the relative sparing of other tissues and organs 
[21]. However, the cause of the common dental impairment 
still remains unclear, as does the endocrine infliction frequ-
ently seen in POLR3 patients.
The CNS MRI findings of POLR3-associated leukodys-
trophies comprise a set of features forming together a highly 
sensitive (84.6%) and specific (92.9%) recognition pattern [9]. 
The characteristic POLR3-leukodystrophy CNS MRI features 
include diffuse supratentorial hypomyelination accompanied 
by relative T2-W hypointensities in the areas of the globus pal-
lidus, ventrolateral nuclei of the thalamus, corticospinal tract 
(at the level of the posterior limb of the internal capsule) and in 
the dentate nucleus and the optic radiation. Cerebellar atrophy 
and thinning of the corpus callosum complete the neurora-
diological pattern characteristic of POLR3-leukodystrophies 
(Tab. 2). Patients not bearing this MRI pattern are unlikely 
to suffer from POLR3-associated leukodystrophy [3, 9, 22]. 
Following standard procedures, CNS MRI was performed 
at the age of 32 months and at seven and 10 years in P1, at 
15 months, 28 months and five years in P2, at 15 years at P3, 
and at eight and 16 years in P4. All our patients meet the ma-
jority of the criteria of the POLR3-associated leukodystrophy 
recognition pattern, with diffuse non-progressive symmetrical 
supratentorial hypomyelination and cerebellar atrophy (Fig. 
2), affecting both vermis and the hemispheres. Cerebellar 
atrophy is slightly more common in POLR3B cases compared 
to POLR3A patients [11]. The degree of white matter hypo-
myelination reached approximately similar levels among all 
the patients. Cerebellar atrophy seems to be less prominent 
in P3 (Fig. 2F), arguably corresponding to a milder cerebellar 
symptomatology in this patient. The typical T2-W hypointens-
ities in the regions of the ventrolateral thalami (Fig. 2E, H), 
the dentate nuclei (Fig. 2I) and the corticospinal tract at the 
level of the posterior limb of the internal capsule (Fig. 2E, H, 
Fig. 3B) were observed in all our patients. Hypointensities in 
the globi pallidi (Fig. 2H, K) were only seen in P3 and P4 (Tab. 
2). Optic radiation involvement, also often accompanying 
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Figure 2. CNS MRI of P1, P2, P3 and P4. Diffuse hypomyelin-
ation (white arrows) visible as white matter T2-weight or FLAIR 
(A, C, D, G, E, H) hyperintensity and T1-weight hypointensity (B) 
is documented in P1 (B), P2 (A, C), P3 (D, E, F) and P4 (G, H, I). 
Mildly asymmetric gyrification compatible with the diagnosis of 
nonlissencephalic cortical dysplasia with polymicrogyria (A; white 
arrowheads) is depicted in P2. Cerebellar atrophy, affecting both 
vermis and the hemispheres, can be observed in FLAIR (C; white 
arrowheads) and T2-weight sequences (F, I; white arrowheads). 
T2-weight hypointensity in the area of nucleus dentatus (I; black 
arrow) can be observed in P4. T2-weight hypointensities in globi 
pallidi (E, H; black arrows), ventrolateral thalami (E, H; black ar-
rowheads) and the corticospinal tract at the level of the posterior 
limb of the internal capsule (E, H; black thin arrows) are demon-
strated in axial images of P3 and P4. Preserved myelination of 
gyrus praecentralis and of the corticospinal tract upstream of 
internal capsule (B; white thin arrow) corresponding to T1-weight 
hyperintensity is observed in P1 
POLR3-leukodystrophies, was not present in either of these 
patients [9]. Thin hypoplastic corpus callosum, described in 
approximately 50% of children younger than 10 years and 
more frequently associated with POLR3B mutations, was 
found in all four patients (Fig. 3A). Interestingly, both P1 and 
P2 expressed additional findings of dysmyelination of the 
white matter with asymmetric gyrification compatible with 
a diagnosis of nonlissencephalic cortical dysplasia in both 
sisters - cortical dysplasia with pachygyria in P1, and cortical 
dysplasia and polymicrogyria in P2 (Fig. 2B). The aetiology of 
these findings was not clarified; nevertheless, cortical dysplasia 
has never been described in any POLR3 patient before. Given 
its simultaneous occurrence in both siblings, the presence of 
another underlying genetic cause cannot be excluded, despite 
negative findings in the whole exome sequencing. P2 was also 
noted to possess a temporobasal enlargement of the external 
cerebrospinal fluid spaces due to an arachnoid cyst (30 x 25 x 
22 mm). However, as arachnoid cysts are not an especially rare 
finding even in healthy asymptomatic populations, they cannot 
be related to POLR3-leukodystrophies. In a subset of patients, 
a small cyst within the splenium has been observed [11].
The onset of POLR3-associated leukodystrophies ranges 
from early childhood to adolescence, with only a minority 
(10%) of patients presenting after 10 years of age. The 
prominent clinical features include progressive motor 
dysfunction or regression with hypotonia and marked ce-
rebellar and pyramidal or extrapyramidal signs, presenting 
as gait abnormalities, ataxia, tremor, dysmetria, abnormal 
eye smooth pursuit, nystagmus or other gaze limitations, 
dystonia, diskinetic movements, spasticity or hyperreflexia 
and others [11] (Tab. 1). 
In spite of the few exceptions documented, POLR3A-as-
sociated disease has been found to be associated with a more 
rapid disease progression, more severe disease course, and 
shorter life expectancy, despite having a slightly later disease 
onset compared to patients bearing mutations in POLR3B. 
Patients from a European background are more likely to have 
mutations in POLR3B [11, 23].
The clinical presentation in both our severely (P1, P2) 
and moderately (P3, P4) impaired patients is in accordance 
with the hitherto described broad phenotypic spectrum of 
POLR3-associated leukodystrophies. 
As with the majority of patients, both siblings manife-
sted early and similarly with developmental delay, cerebellar 
and pyramidal symptomatology and a corresponding dental 
abnormality pattern, which to a lesser extent was also the 
clinical presentation of P4. On the other hand, P3 manifested 
with unprogressive mild to moderate intellectual disability 
with behavioural problems and unspecified clumsiness in 
early childhood, with a subsequent onset of epilepsy at the 
beginning of his second decade and further deterioration of 
cognitive skills and the slow progression of other symptoms. 
No dental abnormalities have been detected in P3 so far, 
although they manifest in around three quarters of patients 
[11] (Tab. 1). Seizures occurred neither in the sibling patients 
(P1, P2), nor in P4. Because epilepsy is present in only appro-
ximately 20% of patients, these patients may remain without 
seizures. However, if epilepsy eventually evolves, it is usually 
well-controllable by pharmacotherapy [11]. Cognitive im-
pairment of POLR3 patients can be of variable severity. Our 
sibling patients manifested a profound intellectual disability, 
while most described patients have developed only a mild 
to moderate impairment, just like P3 and P4. Some patients 
may even have normal cognitive abilities, or only variably ex-
pressed learning difficulties [11]. Intercurrent infections have 
been noted to worsen the disease course, with not all patients 
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Figure 3. CNS MRI in P1, T1-weight sequence. Atrophy of the 
corpus callosum (A; white arrow) and of the cerebellum (A; white 
arrowhead) is demonstrated, together with preserved myelinisa-
tion of the corticospinal tract and its proximity upstream of the 
internal capsule (B; black arrow). Similar findings have been found 
in P2, the sister of P1  
regaining their previous level [11], although this phenomenon 
has not so far been observed in our patients. 
The non-neurological symptoms are dominated by dental 
abnormalities, with an abnormal or delayed deciduous and defi-
nitive teeth eruption, and hypo- /oligodontia and dysmorphic te-
eth, as seen in P1, P2 and P4. Other non-neurological symptoms, 
as observed in P4, may include endocrine dysfunctions such as 
prolactin or growth hormone deficiencies or hypogonadotropic 
hypogonadism, which leads to delayed puberty in three quarters 
of POLR3B patients [11, 24, 25]. Short stature, affecting about 
50% of patients, was a dominant feature in our siblings, as well 
as microcephaly and failure to thrive. Worthy of note concer-
ning the POLR3-leukodystrophies is the substantial diversity in 
disease onset and clinical course severity and progression, inclu-
ding even intrafamilial heterogeneity [11]. Progressive myopia 
seems to be a frequent part of the syndrome, as observed in our 
moderately affected P3 and P4; cataracts can sometimes develop. 
Interestingly, convergent strabismus has not been mentioned yet, 
while optic atrophy, as seen in P1 and P3, has only been described 
occasionally and mostly in older patients [23].
The precise pathophysiological mechanism leading to 
the substantial difference in the clinical phenotype severity 
between P1, P2 with two novel mutations and the other two 
patients, P3 and P4, remains currently elusive and cannot be 
correlated purely to CNS MRI findings, which are of appro-
ximately similar severity. Additional analyses need to be per-
formed. Since POLR3B possesses a high degree of mutational 
heterogeneity with mutational sites distributed throughout the 
whole gene, further studies on more patients are necessary in 
order to determine a precise genotype-phenotype correlation, 
something which cannot be drawn for the time being [5].
Clinical implications and conclusion 
Leukodystrophies are a growing group of heritable white 
matter disorders, for which comprehensive diagnostic al-
gorithms have been created to assist in reaching the proper 
diagnosis as early as possible [1].
In certain cases, the clinical and neuroimaging signs and 
symptoms may assist in narrowing the differential diagnosis 
and focusing the diagnostic process, including the molecular-
-genetic analyses, as witnessed by POLR3-associated leuko-
dystrophies [3, 9]. 
Therefore, awareness of POLR3-associated leukodys-
trophies ought to be increased among clinicians, as this 
particular entity offers highly specific and sensitive clinical 
and neuroimaging recognition patterns, making thereby 
targeted sequencing a method of choice, rather than whole 
exome sequencing. This may be of substantial significance 
not only for clinicians, but also for patients and the general 
healthcare system. 
However, there still are a number of mono-/oligosymp-
tomatic phenotypes, some of them especially with the non-
-neurological presenting symptoms, which may pose a more 
challenging diagnostic task and thus require broader mole-
cular-genetic analyses, such as whole exome sequencing [26]. 
Such sequencing, whether genome, exome or targeted 
panel sequencing, offers a valuable diagnostic tool if properly 
used. Concomitantly, it offers an opportunity to further unra-
vel the underlying genetic and pathophysiological background 
of these disorders, and shift today’s mostly symptomatic care 
towards a search for disease-specific targeted therapies and 
novel therapeutic modalities (for an overview of novel thera-
pies see Helman et al. [27]). 
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